Conditions: Alzheimer Disease
Keywords: antibody
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 198
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.

Detailed description:

Arms:
arm 1: bapineuzumab arm 2: bapineuzumab

Interventions: intervention 1: Bapineuzumab 0.5 mg/kg intervention 2: Bapineuzumab 1.0 m/kg
Intervention descriptions: intervention 1: Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions. intervention 2: I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.

Protocol document: